# Thymosin Alpha-1 Research: Mechanism, Trials and the Weighed Evidence

> Thymosin Alpha-1 research, appraised: the dendritic-cell and IDO mechanism, the hepatitis B and COVID-19 data, the null phase-3 sepsis trial, and the conflation guard against thymosin beta-4 and others.

Mechanism, the trial record, and a disambiguation table — held to what the studies actually measured.

## Start here

This page reads the Thymosin Alpha-1 research record and weighs it. In plain terms: scientists know fairly well *how* this immune peptide works in the lab, they have strong and repeated results in one disease (chronic hepatitis B), and they have mixed or negative results in others (sepsis especially). Below, the mechanism comes first — how the peptide talks to immune cells — then the human trials grouped by setting, then a side-by-side table that keeps Thymosin Alpha-1 separate from the other "thymosin" peptides it is confused with. Where a number appears (a mortality rate, a seroconversion percentage, a hazard ratio), it is tied to a specific study you can check on the [references](/references) page. Nothing here is a treatment instruction.

## Thymosin alpha-1: structure and the thymosin alpha 1 peptide

Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated polypeptide, highly acidic, with no aromatic residues and no disulfide bonds. It is cleaved inside the body from a 113-amino-acid precursor, prothymosin alpha, and the N-terminal acetyl group is essential for its biological activity [1]. Goldstein and colleagues isolated it from calf thymus (thymosin fraction 5) and determined its complete sequence in 1977 — the foundational characterization of the thymosin alpha 1 peptide [1].

## Ta1 peptide and thymalfasin: the same molecule, named for different contexts

The ta1 peptide (Tα1) and **thymalfasin** are the same 28-amino-acid sequence. "Thymalfasin" is the International Nonproprietary Name for the synthetic, sequence-identical drug form used in clinical trials and marketed abroad [4]. Throughout this site the compound is named generically as Thymosin Alpha-1 or thymalfasin; the foreign brand name is not used.

## How it works: dendritic cells, TLR signaling and IDO

Thymosin Alpha-1 acts at the innate-adaptive immune interface. It signals through Toll-like receptors — pattern-recognition sensors, notably TLR2 and TLR9 — on dendritic cells (the immune system's antigen-presenting "alarm-callers") and monocytes, promoting their maturation and antigen presentation, which in turn drives T-cell maturation and Th1 polarization [5]. In parallel it engages the IDO (indoleamine 2,3-dioxygenase) pathway — an enzyme that breaks down the amino acid tryptophan to create a calming, regulatory environment. In dendritic cells, IDO activation required TLR9 and type I interferon receptor signaling and produced interleukin-10 and regulatory T cells, establishing tolerance alongside Th1 priming [5]. That is the dual signature: it can restore effector immunity in an exhausted immune system while damping over-inflammation.

## Thymalfasin in chronic hepatitis B: the strongest signal

The most consistent efficacy is in chronic viral hepatitis. A meta-analysis of lamivudine plus thymalfasin versus lamivudine alone (eight trials, 583 patients) found significantly higher hepatitis B e-antigen seroconversion — 45.1% versus 15.2% (P<0.00001) — and the combination also outperformed entecavir monotherapy in cirrhotic patients [14]. A second meta-analysis of lamivudine plus Thymosin Alpha-1 reported higher end-of-treatment and sustained virological response and reduced viral breakthrough [13]. In these combination regimens the peptide was studied at 1.6 mg subcutaneous twice weekly alongside standard oral antivirals.

## Thymosin alpha 1 covid: mixed evidence

The thymosin alpha 1 covid literature is genuinely mixed, and an appraisal has to say so. A retrospective review of 76 patients with severe COVID-19 associated the peptide with significantly reduced mortality (11.11% versus 30.00%, P=0.044); it increased blood T-cell numbers in patients with severe lymphocytopenia and reduced PD-1 and Tim-3 on CD8+ T cells, reversing T-cell exhaustion [6]. An in-vitro study of SARS-CoV-2-stimulated immune cells found Thymosin Alpha-1 dampened inflammation, lowering TNF-α, IL-6, and IL-8 while raising IL-10 [15]. But these are retrospective and laboratory findings; a 2022 systematic review of roughly 5,300 patients found no statistically significant overall mortality benefit, so the COVID picture should be read as suggestive, not settled.

## Thymosin alpha 1 vs thymosin beta 4 — and the other relatives

The thymosin alpha 1 vs thymosin beta 4 distinction is the most important one to get right, because the two are routinely confused. They are different molecules: Thymosin Alpha-1 is a 28-amino-acid immunomodulatory peptide, while thymosin beta-4 (the research-material label "TB-500") is a 43-amino-acid actin-binding peptide studied for tissue repair — a different sequence, size, and mechanism, and it is thymosin beta-4, not Thymosin Alpha-1, that appears on anti-doping watchlists. In the human mixed lymphocyte reaction the two had opposite effects: Thymosin Alpha-1 enhanced proliferation via helper (T4+) cells, whereas thymosin beta-4 suppressed it via suppressor (T8+) cells [9]. Thymosin Alpha-1 is equally distinct from thymulin (a zinc-dependent nonapeptide), thymopentin (a pentapeptide), thymalin (a separate bovine thymic-extract preparation), and prothymosin alpha (its own 113-amino-acid precursor). They are not interchangeable.

| Peptide | Size | What it is | Notes |
|---|---|---|---|
| Thymosin Alpha-1 (thymalfasin) | 28 aa | Acetylated thymic immunomodulator | The subject of this site; immune, not anabolic |
| Thymosin beta-4 ("TB-500") | 43 aa | Actin-binding repair peptide | Different molecule; the anti-doping-listed one |
| Thymulin (FTS) | 9 aa | Zinc-dependent nonapeptide | Separate peptide; activity depends on zinc |
| Thymopentin (TP-5) | 5 aa | Pentapeptide fragment | Distinct synthetic fragment |
| Thymalin | extract | Bovine thymic-extract preparation | A preparation, not this single peptide |
| Prothymosin alpha | 113 aa | The larger precursor | Thymosin Alpha-1 is cleaved from it |

## Autoimmune tolerance: the lens this site reads through

Through the immune-tolerance-and-autoimmunity lens, several findings cohere. Serum Thymosin Alpha-1 is significantly lower in psoriatic arthritis, rheumatoid arthritis, and systemic lupus erythematosus than in healthy controls (P<0.0001, N=320), lowest in psoriatic arthritis — a deficiency model [8]. In relapsing-remitting multiple sclerosis, adding the peptide to stimulated immune cells reduced pro-inflammatory IL-6, IL-8, and IL-1β, raised regulatory IL-10 and IL-35, and expanded IL-10-producing regulatory B cells [11]. In a mouse model of checkpoint-inhibitor colitis it prevented CTLA-4-induced intestinal autoimmune toxicity through an IDO1-dependent tolerogenic pathway — notably without inducing IDO1 in the tumor itself, illustrating context-dependent regulation [12]. And in mesenchymal stem cells from children with aplastic anemia, it enhanced T-cell suppression through the TLR9/IDO pathway [10]. The thread is tolerance restored through the regulatory arm, not blanket immune stimulation.

## Thymosin alpha 1 reviews: the weighed verdict and the null result

Among thymosin alpha 1 reviews, the honest verdict separates strong from weak evidence. The strongest, most reproducible signal is chronic hepatitis B. The most rigorous test — the phase-3 TESTS trial of 1,106 adults with sepsis — was null: 28-day mortality of 23.4% versus 24.1% on placebo, hazard ratio 0.99 (95% CI 0.77–1.27, P=0.93) [3], a result that did not confirm the marginally significant 26.0%-versus-35.0% mortality difference from the earlier 361-patient ETASS trial [2]. A comprehensive four-decade review documents the dosing range and the benign safety profile while acknowledging the literature is heterogeneous and often single-region [4]. The appraisal: real, mechanistically coherent, strongest in viral hepatitis, suggestive in COVID and autoimmune tolerance, and not demonstrated in sepsis.

---

Thymosin Alpha-1 Reviews is an evidence-appraisal desk that weighs the published thymalfasin record — strongest in chronic hepatitis B, null in the largest sepsis trial — held by no clinic and selling no product.